Comparison of Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand
This study is currently recruiting participants.
Verified November 2012 by Mettapracharak Hospital
Sponsor:
Mettapracharak Hospital
Collaborators:
Thailand Research Fund
Prince of Songkla University
Information provided by (Responsible Party):
Dr. Sunisa Sintuwong, Mettapracharak Hospital
ClinicalTrials.gov Identifier:
NCT01312545
First received: March 7, 2011
Last updated: November 29, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study wants to compare between two types of implants in enucleation. Both of them are made from porous polyethylene but have different fabricating techniques. The investigators chose an exposure rate as a main outcome because the investigators think it is the most important outcome for the surgeons. The study hypothesis is: Is the exposure rate of a local-made polyethylene orbital implant the same as an imported one?
| Condition | Intervention | Phase |
|---|---|---|
|
Phthisis Bulbi |
Device: 3DP Device: Medpor |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Comparison of Exposure Rate Between Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand: A Randomized, Equivalence Controlled Trial and Multicenter Study |
Resource links provided by NLM:
Further study details as provided by Mettapracharak Hospital:
Primary Outcome Measures:
- Exposure rate [ Time Frame: From date of surgery until the date of first exposure, assessed up to 12 months ] [ Designated as safety issue: No ]Exposure was defined as the separation of tissue over the anterior surface of an implant.
Secondary Outcome Measures:
- Infection rate [ Time Frame: From date of surgery until the date of first infection, assessed up to 12 months ] [ Designated as safety issue: No ]Infection was defined as the presence of pus or abscess at or around an impalnt. It can be diagnosed clinically or confirmed by the histopathology report after explantation.
- Motility [ Time Frame: 2,3,6,9,12 months post surgery ] [ Designated as safety issue: No ]Motility was defined as the distance in millimeters the patients can move their eyes in abduction, adduction, supraduction and infraduction. The rulers will be attached to the slit lamp in horizontal and vertical axis.The observer then take a photo of patients in 4 directions, with and without prosthesis. Two independent observers will measure motilities from the photographs. If the difference from two independent observers is more than 2 standard deviation, the measurement process will be started again.
- Gadolinium enhancement [ Time Frame: 6, 12 months post surgery ] [ Designated as safety issue: No ]Gadolinium uptake from MRI orbit represents implant vascularization. They will be taken in axial, coronal and sagittal plane with standard protocol MRI study. In T1-weighted post contrast image, an equatorial image will be identified. The equatorial image was defined as the image at the level of implant size devided by two, measured from the anterior surface. Two independent observer will mark between contrast and non-contrast area. Then area of enhancement was calculated by subtracting non-enhancement area from total equatorial surface area.
| Estimated Enrollment: | 130 |
| Study Start Date: | March 2011 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: local made implant |
Device: 3DP
intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
|
| Experimental: imported implant |
Device: Medpor
commercial porous polyethylene
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical diagnosis of phthisis bulbi, painful blindness, intraocular tumor without metastasis and severe ruptured eyeball
- Must speak and understand Thai language well
- Must have good consciousness
Exclusion Criteria:
- Has a history of prior enucleation or evisceration
- Cannot follow up for at least one year
- Has recent eye infection within 6 months
- Need additional surgery eg. fornix reconstruction, etc.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01312545
Contacts
| Contact: Sunisa Sintuwong, MD | 66 34 225818 ext 7168 | drsunisa@gmail.com |
Locations
| Thailand | |
| Mettapracharak Eye Center, Mettapracharak (Wat Raikhing) Hospital | Recruiting |
| Amphoe Sam Phran, Nakhon Pathom, Thailand, 73210 | |
| Contact: Sunisa Sintuwong, M.D. 66 34 225 818 ext 7168 drsunisa@gmail.com | |
| Contact: Kanjana Leelapatranurak, MD 66 34 225 818 kanjana_nue@yahoo.com | |
| Principal Investigator: Sunisa Sintuwong, MD | |
Sponsors and Collaborators
Mettapracharak Hospital
Thailand Research Fund
Prince of Songkla University
Investigators
| Principal Investigator: | Sunisa Sintuwong, MD | Mettapracharak (Wat Raikhing) Hospital |
More Information
No publications provided
| Responsible Party: | Dr. Sunisa Sintuwong, Dr., Mettapracharak Hospital |
| ClinicalTrials.gov Identifier: | NCT01312545 History of Changes |
| Other Study ID Numbers: | MEC1/2011 |
| Study First Received: | March 7, 2011 |
| Last Updated: | November 29, 2012 |
| Health Authority: | Thailand: Ethical Committee |
Keywords provided by Mettapracharak Hospital:
|
orbital implant evisceration economic polyethylene porous |
Additional relevant MeSH terms:
|
Tuberculosis, Pulmonary Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections |
Bacterial Infections Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |
ClinicalTrials.gov processed this record on May 16, 2013